Cancer Profiling and Pathways: Technologies and Global Markets
REPORT SCOPE:
Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.?
Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.
The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.
This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also examines recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.
REPORT INCLUDES:
Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size and competitive landscape, a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments is needed. Microarray technologies provide analysis of tens of thousands of molecules for a variety of assays, including drug binding, molecular interactions, enzyme activity and pathway identification. These microarrays, which include DNA microarrays, protein microarrays, tissue microarrays, low complexity microarrays and carbohydrate microarrays, are excellent tools for gene expression profiling, biomarker profiling and diagnostics.?
Pharmaceutical and biotechnology researchers use microarrays to streamline drug target identification, selection, validation and predictive testing. Rapid growth in the clinical research and diagnostic devices markets holds great potential for applications of microarray technology, including basic research, clinical trials and diagnostic devices. This report examines various microarray platforms and the technologies that are utilized to detect DNA and proteins for the purpose of drug discovery, disease diagnosis and disease monitoring. This report also examines companies that are actively developing and marketing microarray instrumentation or microarray biochips.
The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players and competitive outlook. This report will also provide market tables and also provides company profiles.
This report analyzes the cancer profiling and pathways market: technologies market, tools market, and application market (diagnosis, drug development and discovery). This report also examines recent studies, microRNA detection and profiling, clinically oriented microRNA profiling in several human cancers. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. Relationship between miRNAs and epigenetics is also examined. This report categorizes the market for epigenetics, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. This report also looks at SNPs analysis instruments, reagents, software and services, providing information critical to understanding the business behind this new technology.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.
REPORT INCLUDES:
- 91 tables
- An overview of the global market for cancer profiling and pathways
- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of products in this market, newly emerging tools, diagnostics and therapeutics, and their impacts on the market
- Examination of evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, which are integral to deciphering molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers
- Identification of important cancer profiling techniques, market shares by types of products on the market, and market shares by company, as well as types of cancers and biomarkers
- Coverage of epigenetic, methylation, and miRNA products in development, products in clinical trials and currently marketed, and clinical-stage development products
- Company profiles of key players in the market
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing the Study
Scope of Report
Intended Audience
Methodology
Information Sources
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Cancer Profiling and Pathways
CHAPTER 3 OVERVIEW
Introduction
Biomarkers
Guidelines
Screening Tests
Early Detection and Diagnosis of Cancer
Pathway Profiling
Linking Cancer Disease through Pathway Profiling
Molecular Profiling
Historical Facts
Molecular Profiles
Cancer Profiling
Challenges
Clinical Utility of Molecular Profiling
Pathological Classification
Molecular Profiling Approaches
Cancer Profiling: Future Goals
CHAPTER 4 CURRENT PROFILING TECHNIQUES
Genomics
Genomic Profiling
Microarrays
Comparative Genomic Hybridization (CGH)
Key Companies
Key Players
Microarrays to Clinical Problems
Single Nucleotide Polymorphism (SNP)
Multi-color FISH
Companies
DNA Sequencing
Emerging DNA Sequencing Technologies
High-throughput Sequencing
Other Sequencing Technologies
Cancer Applications
Next-Gen Sequencing
Next-Generation Companies
ABI/SOLiD
Other Methods
Patents and Sequencing
Summary
Next-Generation Sequencing Technologies
Next-Generation Sequencing: Future
Genomics and Cancer—Some Examples
Mutations Predicting Resistance to Targeted Therapies
Sequencing and the Clinic
Transcriptomic Profiling
Microarray-based Gene Expression Profiling
Tiling Arrays
qRT-PCR
Cancer Applications
Emerging Microarray Technologies
Future
CHAPTER 5 EPIGENOMIC PROFILING
Overview and Introduction to the Epigenetics Landscape
Cancer Applications
DNA Methylation
microRNA
Epigenetic Changes and Cancer Stem Cells
Epigenetic Therapy for Cancer
Leading Epigenetic Companies
Epigenetics and MicroRNA Profiling—Finding Pathways to Treatment
MicroRNAs and Therapeutic Applications in Cancer
MicroRNAs as Prognostic and Therapeutic Biomarkers
Anti-Cancer Drugs and microRNA Targets
Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
Diagnostic and Therapeutic microRNA Strategies in Cancer
Therapeutic Potential
Therapeutic Strategies
MicroRNAs in Disease Diagnostics
Circulating microRNAs
MicroRNA Profiling Methods
Clinical microRNA Diagnostics
MicroRNAs in Therapeutics
MicroRNA Patents and Outlook
Future
Methylation Markers
DNA Methylation, an Epigenetic Process
Current Methods and Products
Clinical Implications
Future Directions
Epigenetic Diagnostic Development
Epigenetic Drugs
HDAC Inhibitors
Epigenetic Therapeutic Development
Key Players
CHAPTER 6 PROTEOMICS
Proteomics and Protein Profiling
Proteomics Protein Profiling Approaches
Techniques
Applications of Proteomic Techniques in Cancer Research
Technologies and Limitations
Proteomics and Initiatives
Cancer Applications
Proteomics in the Treatment of Cancer
Clinical Applications of Proteomics
Proteomic Approaches in Therapeutic Targets
Key Players
Proteomics-Based Diagnostic Products
Proteomic Research Centers
Clinical Trial Using Proteomics Technologies for Personalized Medicine
Proteomics and Medicine
Proteomics Market
CHAPTER 7 GLYCOMICS
What is Glycomics?
Techniques
Analytical High-Throughput Technologies
Emergence of Glycoarrays
Glycoinformatics
Biomedical Applications
Glycomics’s Relationship with Other “Omics” Technologies
Glycomics for Biomarker Discovery
Cancer and Glycomics
Glycomics-Biomarkers for Ovarian Cancer
U.S. Patents on Glycomics
CHAPTER 8 METABOLOMICS
What is Metabolomics?
Metabolome
Techniques
Detection Methods
Metabolomics and Drug Discovery
Biomarker Identification
CHAPTER 9 BIOINFORMATICS, DATABASES AND PATHWAY ANALYSIS
CHAPTER 10 CANCER PROFILING AND CLINICAL DEVELOPMENT
Biomarkers
Cancer and Biomarkers
CHAPTER 11 MARKET
Global DNA Diagnostics Market
The Cancer Diagnostics Market
Cancer Diagnostic Tests
The Cancer/Tumor Profiling Market
Personalized Medicine
Cancer Biomarker Testing Market
Genomics Market
SNP Genotyping and Analysis Market
Microarray/Biochips Market
Diagnostic Microarrays
DNA Sequencing Market
PCR Market
Epigenetics and Market
miRNA Market
Epigenetics and Cancer Market and Future Growth
Proteomics in the Pharma Industry
Protein Microarrays and Trends
The Metabolomics Market
Future
Conclusion
Study Goals and Objectives
Reasons for Doing the Study
Scope of Report
Intended Audience
Methodology
Information Sources
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Cancer Profiling and Pathways
CHAPTER 3 OVERVIEW
Introduction
Biomarkers
Guidelines
Screening Tests
Early Detection and Diagnosis of Cancer
Pathway Profiling
Linking Cancer Disease through Pathway Profiling
Molecular Profiling
Historical Facts
Molecular Profiles
Cancer Profiling
Challenges
Clinical Utility of Molecular Profiling
Pathological Classification
Molecular Profiling Approaches
Cancer Profiling: Future Goals
CHAPTER 4 CURRENT PROFILING TECHNIQUES
Genomics
Genomic Profiling
Microarrays
Comparative Genomic Hybridization (CGH)
Key Companies
Key Players
Microarrays to Clinical Problems
Single Nucleotide Polymorphism (SNP)
Multi-color FISH
Companies
DNA Sequencing
Emerging DNA Sequencing Technologies
High-throughput Sequencing
Other Sequencing Technologies
Cancer Applications
Next-Gen Sequencing
Next-Generation Companies
ABI/SOLiD
Other Methods
Patents and Sequencing
Summary
Next-Generation Sequencing Technologies
Next-Generation Sequencing: Future
Genomics and Cancer—Some Examples
Mutations Predicting Resistance to Targeted Therapies
Sequencing and the Clinic
Transcriptomic Profiling
Microarray-based Gene Expression Profiling
Tiling Arrays
qRT-PCR
Cancer Applications
Emerging Microarray Technologies
Future
CHAPTER 5 EPIGENOMIC PROFILING
Overview and Introduction to the Epigenetics Landscape
Cancer Applications
DNA Methylation
microRNA
Epigenetic Changes and Cancer Stem Cells
Epigenetic Therapy for Cancer
Leading Epigenetic Companies
Epigenetics and MicroRNA Profiling—Finding Pathways to Treatment
MicroRNAs and Therapeutic Applications in Cancer
MicroRNAs as Prognostic and Therapeutic Biomarkers
Anti-Cancer Drugs and microRNA Targets
Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
Diagnostic and Therapeutic microRNA Strategies in Cancer
Therapeutic Potential
Therapeutic Strategies
MicroRNAs in Disease Diagnostics
Circulating microRNAs
MicroRNA Profiling Methods
Clinical microRNA Diagnostics
MicroRNAs in Therapeutics
MicroRNA Patents and Outlook
Future
Methylation Markers
DNA Methylation, an Epigenetic Process
Current Methods and Products
Clinical Implications
Future Directions
Epigenetic Diagnostic Development
Epigenetic Drugs
HDAC Inhibitors
Epigenetic Therapeutic Development
Key Players
CHAPTER 6 PROTEOMICS
Proteomics and Protein Profiling
Proteomics Protein Profiling Approaches
Techniques
Applications of Proteomic Techniques in Cancer Research
Technologies and Limitations
Proteomics and Initiatives
Cancer Applications
Proteomics in the Treatment of Cancer
Clinical Applications of Proteomics
Proteomic Approaches in Therapeutic Targets
Key Players
Proteomics-Based Diagnostic Products
Proteomic Research Centers
Clinical Trial Using Proteomics Technologies for Personalized Medicine
Proteomics and Medicine
Proteomics Market
CHAPTER 7 GLYCOMICS
What is Glycomics?
Techniques
Analytical High-Throughput Technologies
Emergence of Glycoarrays
Glycoinformatics
Biomedical Applications
Glycomics’s Relationship with Other “Omics” Technologies
Glycomics for Biomarker Discovery
Cancer and Glycomics
Glycomics-Biomarkers for Ovarian Cancer
U.S. Patents on Glycomics
CHAPTER 8 METABOLOMICS
What is Metabolomics?
Metabolome
Techniques
Detection Methods
Metabolomics and Drug Discovery
Biomarker Identification
CHAPTER 9 BIOINFORMATICS, DATABASES AND PATHWAY ANALYSIS
CHAPTER 10 CANCER PROFILING AND CLINICAL DEVELOPMENT
Biomarkers
Cancer and Biomarkers
CHAPTER 11 MARKET
Global DNA Diagnostics Market
The Cancer Diagnostics Market
Cancer Diagnostic Tests
The Cancer/Tumor Profiling Market
Personalized Medicine
Cancer Biomarker Testing Market
Genomics Market
SNP Genotyping and Analysis Market
Microarray/Biochips Market
Diagnostic Microarrays
DNA Sequencing Market
PCR Market
Epigenetics and Market
miRNA Market
Epigenetics and Cancer Market and Future Growth
Proteomics in the Pharma Industry
Protein Microarrays and Trends
The Metabolomics Market
Future
Conclusion
LIST OF TABLES
Summary Table: Global Cancer Profiling Technologies Market, by Type, Through 2023
Table 1: Technical Approaches for Tumor Molecular Profiling
Table 2: Different Tools for Molecular Profiling of Cancer
Table 3: Genomics: Technologies
Table 4: Applications Market
Table 5: Segment Types
Table 6: List of Techniques/Tools for Genomic Profiling
Table 7: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 8: Commonly Used DNA Microarrays
Table 9: Genomic Tests
Table 10: Selected Companies with Microarray Technologies
Table 11: Key Companies
Table 12: Companies with Sequencing Technologies Next-Generation Sequencers
Table 13: Sequencing Patents Awarded
Table 14: Mutations Identified in Cancer
Table 15: Consortium Listed Responsibilities
Table 16: Transcriptomic Techniques
Table 17: miRNA and siRNA-a Comparison
Table 18: Epigenetic Drugs Approved by the U.S. FDA
Table 19: HDAC Inhibitors
Table 20: Selected Epigenetic Companies
Table 21: Currently Used microRNA Techniques
Table 22: MicroRNA Expression in Cancer
Table 23: Epi-miRNAs Regulating Effectors of the Epigenetic Machinery
Table 24: List of Predicted Targets That are Known Genes Affected in Colon Cancer
Table 25: List of Predicted Targets That are Known Genes Affected in Pancreatic Cancer
Table 26: miRNAs Differentially Expressed Between CRC and Normal Colorectal Tissue
Table 27: miRNAs Differentially Expressed Between Normal Colon and Early-Stage Colorectal Cancer (Stages I and II)
Table 28: miRNAs Differentially Expressed in Early- (I and II) Vs Late-Stage (III and IV) Disease
Table 29: Pathways Targeted by CRC miRNAs
Table 30: MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management
Table 31: MicroRNAs (miRs) with Altered Expression in Ovarian Carcinoma
Table 32: MicroRNA-based Therapeutics: Development Status
Table 33: Selected microRNAs in Development and Cancer
Table 34: microRNA Patents
Table 35: Global microRNA Market for Cancer Profiling Technologies, Through 2023
Table 36: Selected Companies for miRNA-Specific Tools and Reagents
Table 37: Intrinsic Classification of Breast Cancer, by Gene Expression Profiles and Cell Surface Hormonal Expression
Table 38: Select Epigenetic-based Diagnostic Companies
Table 39: Selected Methylation Tests for Cancer
Table 40: Global Epigenetics Market for Cancer Profiling Technologies, Through 2023
Table 41: Epigenetic Drugs for Cancer-Approved/Late-Stage Clinical Trials
Table 42: Methylation Markers in Development
Table 43: Selected Companies with Methylation Products
Table 44: Methylation Markers/Tests-Patents
Table 45: Biomarker Identified Using Two-Dimensional Electrophoresis (2-DE)
Table 46: Biomarker Identified using Mass Spectroscopy (MS)
Table 47: Antibody Array Vendors
Table 48: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 49: The Seven Tumor Glycome Laboratories
Table 50: Clinical Trials and Glycomics
Table 51: U.S. Patents on Glycomics
Table 52: Key Predictive Biomarkers for Trastuzumab Therapy
Table 53: Predictive Biomarkers for EGFR TKI Therapies in Lung Cancer
Table 54: Global DNA Diagnostics Market, Through 2023
Table 55: Cancer Profiling Market: Segment Types
Table 56: Global Cancer Profiling Technologies Market, Through 2023
Table 57: Cancer Profiling Market: Applications
Table 58: Cancer Profiling Market: Technologies
Table 59: Global Biomarkers Market, Through 2023
Table 60: Selected Players
Table 61: U.S. Biomarker Cancer Testing Market, Through 2023
Table 62: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 63: Global SNP Genotyping Market, Through 2023
Table 64: Global Biochips Market, Through 2023
Table 65: Microarray Markets
Table 66: Some Major BioChip Companies
Table 67: Microarrays: Modalities
Table 68: Global Diagnostic Microarray Market for Cancer Profiling Technologies, Through 2023
Table 69: Some Commercially Available Cancer Diagnostic Devices Based on Microarray Technology
Table 70: Microarray Technologies: Key Companies and Products
Table 71: Global DNA Microarray Market, Through 2023
Table 72: MicroArray Products
Table 73: Global Next-Generation Sequencing Market, Through 2023
Table 74: The Next-Generation Sequencing (NGS) Market: Platforms
Table 75: Next-Generation Sequencing-Based Target Enrichment Industry Company Platform Method
Table 76: Noninvasive Prenatal Diagnostics Potential Future Competitors
Table 77: Global Polymerase Chain Reaction Market, Through 2023
Table 78: Key PCR Companies
Table 79: Real-Time (QRTPCR) PCR Selected Companies
Table 80: Global Digital (d)PCR and qPCR Market, Through 2023
Table 81: Global Epigenetics Market, Through 2023
Table 82: Epigenetics Arrays and Selected Cancer Profiling Companies
Table 83: Epigenetic Drugs: Approved by the FDA and Commercially Available
Table 84: Epigenetics and Selected Companies
Table 85: Epigenetic Diagnostic Tests
Table 86: Global miRNA Market for Cancer Profiling Technologies, Through 2023
Table 87: miRNA Market Segments
Table 88: Selected Companies with Methylation Products
Table 89: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 90: Selected Companies Offering, Developing or Partnering to Develop Companion Diagnostics
Summary Table: Global Cancer Profiling Technologies Market, by Type, Through 2023
Table 1: Technical Approaches for Tumor Molecular Profiling
Table 2: Different Tools for Molecular Profiling of Cancer
Table 3: Genomics: Technologies
Table 4: Applications Market
Table 5: Segment Types
Table 6: List of Techniques/Tools for Genomic Profiling
Table 7: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 8: Commonly Used DNA Microarrays
Table 9: Genomic Tests
Table 10: Selected Companies with Microarray Technologies
Table 11: Key Companies
Table 12: Companies with Sequencing Technologies Next-Generation Sequencers
Table 13: Sequencing Patents Awarded
Table 14: Mutations Identified in Cancer
Table 15: Consortium Listed Responsibilities
Table 16: Transcriptomic Techniques
Table 17: miRNA and siRNA-a Comparison
Table 18: Epigenetic Drugs Approved by the U.S. FDA
Table 19: HDAC Inhibitors
Table 20: Selected Epigenetic Companies
Table 21: Currently Used microRNA Techniques
Table 22: MicroRNA Expression in Cancer
Table 23: Epi-miRNAs Regulating Effectors of the Epigenetic Machinery
Table 24: List of Predicted Targets That are Known Genes Affected in Colon Cancer
Table 25: List of Predicted Targets That are Known Genes Affected in Pancreatic Cancer
Table 26: miRNAs Differentially Expressed Between CRC and Normal Colorectal Tissue
Table 27: miRNAs Differentially Expressed Between Normal Colon and Early-Stage Colorectal Cancer (Stages I and II)
Table 28: miRNAs Differentially Expressed in Early- (I and II) Vs Late-Stage (III and IV) Disease
Table 29: Pathways Targeted by CRC miRNAs
Table 30: MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management
Table 31: MicroRNAs (miRs) with Altered Expression in Ovarian Carcinoma
Table 32: MicroRNA-based Therapeutics: Development Status
Table 33: Selected microRNAs in Development and Cancer
Table 34: microRNA Patents
Table 35: Global microRNA Market for Cancer Profiling Technologies, Through 2023
Table 36: Selected Companies for miRNA-Specific Tools and Reagents
Table 37: Intrinsic Classification of Breast Cancer, by Gene Expression Profiles and Cell Surface Hormonal Expression
Table 38: Select Epigenetic-based Diagnostic Companies
Table 39: Selected Methylation Tests for Cancer
Table 40: Global Epigenetics Market for Cancer Profiling Technologies, Through 2023
Table 41: Epigenetic Drugs for Cancer-Approved/Late-Stage Clinical Trials
Table 42: Methylation Markers in Development
Table 43: Selected Companies with Methylation Products
Table 44: Methylation Markers/Tests-Patents
Table 45: Biomarker Identified Using Two-Dimensional Electrophoresis (2-DE)
Table 46: Biomarker Identified using Mass Spectroscopy (MS)
Table 47: Antibody Array Vendors
Table 48: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 49: The Seven Tumor Glycome Laboratories
Table 50: Clinical Trials and Glycomics
Table 51: U.S. Patents on Glycomics
Table 52: Key Predictive Biomarkers for Trastuzumab Therapy
Table 53: Predictive Biomarkers for EGFR TKI Therapies in Lung Cancer
Table 54: Global DNA Diagnostics Market, Through 2023
Table 55: Cancer Profiling Market: Segment Types
Table 56: Global Cancer Profiling Technologies Market, Through 2023
Table 57: Cancer Profiling Market: Applications
Table 58: Cancer Profiling Market: Technologies
Table 59: Global Biomarkers Market, Through 2023
Table 60: Selected Players
Table 61: U.S. Biomarker Cancer Testing Market, Through 2023
Table 62: Global Genomics Market for Cancer Profiling Technologies, Through 2023
Table 63: Global SNP Genotyping Market, Through 2023
Table 64: Global Biochips Market, Through 2023
Table 65: Microarray Markets
Table 66: Some Major BioChip Companies
Table 67: Microarrays: Modalities
Table 68: Global Diagnostic Microarray Market for Cancer Profiling Technologies, Through 2023
Table 69: Some Commercially Available Cancer Diagnostic Devices Based on Microarray Technology
Table 70: Microarray Technologies: Key Companies and Products
Table 71: Global DNA Microarray Market, Through 2023
Table 72: MicroArray Products
Table 73: Global Next-Generation Sequencing Market, Through 2023
Table 74: The Next-Generation Sequencing (NGS) Market: Platforms
Table 75: Next-Generation Sequencing-Based Target Enrichment Industry Company Platform Method
Table 76: Noninvasive Prenatal Diagnostics Potential Future Competitors
Table 77: Global Polymerase Chain Reaction Market, Through 2023
Table 78: Key PCR Companies
Table 79: Real-Time (QRTPCR) PCR Selected Companies
Table 80: Global Digital (d)PCR and qPCR Market, Through 2023
Table 81: Global Epigenetics Market, Through 2023
Table 82: Epigenetics Arrays and Selected Cancer Profiling Companies
Table 83: Epigenetic Drugs: Approved by the FDA and Commercially Available
Table 84: Epigenetics and Selected Companies
Table 85: Epigenetic Diagnostic Tests
Table 86: Global miRNA Market for Cancer Profiling Technologies, Through 2023
Table 87: miRNA Market Segments
Table 88: Selected Companies with Methylation Products
Table 89: Global Proteomics Market for Cancer Profiling Technologies, Through 2023
Table 90: Selected Companies Offering, Developing or Partnering to Develop Companion Diagnostics
LIST OF FIGURES
Summary Figure: Global Cancer Profiling Technologies Market, by Type, 2017-2023
Figure 1: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 2: Global microRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 3: Global Epigenetics Market for Cancer Profiling Technologies, 2017-2023
Figure 4: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
Figure 5: Global DNA Diagnostics Market, 2017-2023
Figure 6: Global Biomarkers Market, 2017-2023
Figure 7: U.S. Biomarker Cancer Testing Market, 2017-2023
Figure 8: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 9: Global SNP Genotyping Market, 2017-2023
Figure 10: Global Biochips Market, 2017-2023
Figure 11: Global Diagnostic Microarray Market for Cancer Profiling Technologies, 2017-2023
Figure 12: Global DNA Microarray Market, 2017-2023
Figure 13: Global Next-Generation Sequencing Market, 2017-2023
Figure 14: Global Polymerase Chain Reaction Market, 2017-2023
Figure 15: Global Digital (d)PCR and qPCR Market, 2017-2023
Figure 16: Global Epigenetics Market, 2017-2023
Figure 17: Global miRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 18: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
Summary Figure: Global Cancer Profiling Technologies Market, by Type, 2017-2023
Figure 1: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 2: Global microRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 3: Global Epigenetics Market for Cancer Profiling Technologies, 2017-2023
Figure 4: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
Figure 5: Global DNA Diagnostics Market, 2017-2023
Figure 6: Global Biomarkers Market, 2017-2023
Figure 7: U.S. Biomarker Cancer Testing Market, 2017-2023
Figure 8: Global Genomics Market for Cancer Profiling Technologies, 2017-2023
Figure 9: Global SNP Genotyping Market, 2017-2023
Figure 10: Global Biochips Market, 2017-2023
Figure 11: Global Diagnostic Microarray Market for Cancer Profiling Technologies, 2017-2023
Figure 12: Global DNA Microarray Market, 2017-2023
Figure 13: Global Next-Generation Sequencing Market, 2017-2023
Figure 14: Global Polymerase Chain Reaction Market, 2017-2023
Figure 15: Global Digital (d)PCR and qPCR Market, 2017-2023
Figure 16: Global Epigenetics Market, 2017-2023
Figure 17: Global miRNA Market for Cancer Profiling Technologies, 2017-2023
Figure 18: Global Proteomics Market for Cancer Profiling Technologies, 2017-2023
